News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
858,309 Results
Type
Article (87260)
Company Profile (732)
Press Release (770291)
Multimedia
Podcasts (165)
Webinars (26)
Section
Business (232988)
Career Advice (4137)
Deals (39782)
Drug Delivery (133)
Drug Development (91212)
Employer Resources (201)
FDA (18248)
Job Trends (17388)
News (397223)
Policy (39902)
Tag
Academia (3003)
Academic (2)
Accelerated approval (17)
Adcomms (35)
Allergies (119)
Alliances (56979)
ALS (137)
Alzheimer's disease (1649)
Antibody-drug conjugate (ADC) (206)
Approvals (18243)
Artificial intelligence (457)
Autoimmune disease (49)
Automation (23)
Bankruptcy (406)
Best Places to Work (12633)
BIOSECURE Act (22)
Biosimilars (147)
Biotechnology (483)
Bladder cancer (118)
Brain cancer (47)
Breast cancer (439)
Cancer (3554)
Cardiovascular disease (312)
Career advice (3551)
Career pathing (36)
CAR-T (230)
CDC (49)
Cell therapy (631)
Cervical cancer (29)
Clinical research (74967)
Collaboration (1290)
Company closure (4)
Compensation (862)
Complete response letters (51)
COVID-19 (2941)
CRISPR (78)
C-suite (512)
Cystic fibrosis (130)
Data (3829)
Decentralized trials (2)
Denatured (59)
Depression (100)
Diabetes (427)
Diagnostics (7048)
Digital health (30)
Diversity (11)
Diversity, equity & inclusion (49)
Drug discovery (216)
Drug pricing (169)
Drug shortages (36)
Duchenne muscular dystrophy (183)
Earnings (98644)
Editorial (53)
Employer branding (25)
Employer resources (169)
Events (132447)
Executive appointments (957)
FDA (20495)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (4)
Frontotemporal dementia (11)
Funding (1141)
Gene editing (165)
Generative AI (45)
Gene therapy (499)
GLP-1 (1000)
Government (5350)
Grass and pollen (7)
Guidances (334)
Healthcare (20934)
HIV (48)
Huntington's disease (34)
IgA nephropathy (52)
Immunology and inflammation (225)
Immuno-oncology (18)
Indications (46)
Infectious disease (3160)
Inflammatory bowel disease (179)
Inflation Reduction Act (13)
Influenza (87)
Intellectual property (167)
Interviews (815)
IPO (17922)
IRA (59)
Job creations (5196)
Job search strategy (2863)
Kidney cancer (15)
Labor market (70)
Layoffs (628)
Leadership (31)
Legal (10144)
Liver cancer (90)
Longevity (12)
Lung cancer (512)
Lymphoma (251)
Machine learning (23)
Management (65)
Manufacturing (574)
MASH (120)
Medical device (14830)
Medtech (14848)
Mergers & acquisitions (22678)
Metabolic disorders (1086)
Multiple sclerosis (118)
NASH (23)
Neurodegenerative disease (185)
Neuropsychiatric disorders (50)
Neuroscience (2553)
NextGen: Class of 2025 (7687)
Non-profit (5095)
Now hiring (54)
Obesity (542)
Opinion (304)
Ovarian cancer (114)
Pain (156)
Pancreatic cancer (146)
Parkinson's disease (215)
Partnered (27)
Patents (386)
Patient recruitment (272)
Peanut (57)
People (66077)
Pharmaceutical (143)
Pharmacy benefit managers (25)
Phase I (23112)
Phase II (32555)
Phase III (24502)
Pipeline (2474)
Policy (282)
Postmarket research (3554)
Preclinical (10439)
Press Release (72)
Prostate cancer (175)
Psychedelics (49)
Radiopharmaceuticals (281)
Rare diseases (601)
Real estate (7412)
Recruiting (76)
Regulatory (27706)
Reports (64)
Research institute (2676)
Resumes & cover letters (650)
Rett syndrome (12)
RNA editing (15)
RSV (64)
Schizophrenia (121)
Series A (189)
Series B (141)
Service/supplier (30)
Sickle cell disease (75)
Special edition (25)
Spinal muscular atrophy (168)
Sponsored (40)
Startups (4315)
State (2)
Stomach cancer (17)
Supply chain (95)
Tariffs (83)
The Weekly (104)
Vaccines (1011)
Venture capital (63)
Weight loss (377)
Women's health (56)
Worklife (21)
Date
Today (141)
Last 7 days (504)
Last 30 days (2501)
Last 365 days (33868)
2025 (23848)
2024 (38139)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1278)
Alabama (78)
Alaska (7)
Arizona (297)
Arkansas (14)
Asia (50809)
Australia (8924)
California (8942)
Canada (2713)
China (844)
Colorado (379)
Connecticut (399)
Delaware (242)
Europe (116688)
Florida (1316)
Georgia (305)
Hawaii (3)
Idaho (67)
Illinois (787)
India (46)
Indiana (432)
Iowa (19)
Japan (270)
Kansas (123)
Kentucky (35)
Louisiana (20)
Maine (75)
Maryland (1218)
Massachusetts (6738)
Michigan (297)
Minnesota (541)
Mississippi (4)
Missouri (113)
Montana (32)
Nebraska (26)
Nevada (102)
New Hampshire (76)
New Jersey (2465)
New Mexico (32)
New York (2432)
North Carolina (1366)
North Dakota (10)
Northern California (3976)
Ohio (281)
Oklahoma (19)
Oregon (49)
Pennsylvania (1862)
Puerto Rico (18)
Rhode Island (44)
South America (1655)
South Carolina (45)
South Dakota (1)
Southern California (3405)
Tennessee (142)
Texas (1400)
United States (33164)
Utah (267)
Virginia (239)
Washington D.C. (82)
Washington State (769)
West Virginia (4)
Wisconsin (92)
There are 858,309 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Neurodegenerative disease
VectorY Bets up to $1.2B+ That Shape’s Brain-Penetrant Capsids Are a Fit
VectorY Therapeutics will evaluate the use of SHP-DB1, a capsid developed by Shape Therapeutics, to deliver therapies to the brain, including VectorY’s developmental Huntington’s and Alzheimer’s disease treatments.
September 18, 2025
·
2 min read
·
Dan Samorodnitsky
Layoffs
Layoffs From Just 6 Pharmas Could Wipe Out Over 39,000 Jobs
This year, Novo Nordisk and Merck announced significant layoffs, with Novo planning to axe about 9,000 employees and Merck projecting it could let go of roughly 6,000. Meanwhile, Bayer, Bristol Myers Squibb, Novartis and Pfizer have also made noteworthy cuts.
September 18, 2025
·
9 min read
·
Angela Gabriel
PODCAST
What Do AI and Hammers Have in Common?
In this episode of Denatured, BioSpace’s head of insights Lori Ellis and Colin Zick, partner at Foley Hoag LLP, spend time discussing some of the points brought up in the Bioprocessing Summit last month. They explore the connections between hammers, AI, The Planet of the Apes and monoliths.
September 18, 2025
·
1 min read
·
Lori Ellis
Press Releases
American Aires Inc. Announces Resignation of Director and Update on Annual General Meeting of Shareholders
September 18, 2025
·
3 min read
Press Releases
Phio Pharmaceuticals to Present at the Life Sciences Future Conference
Key updates to include advances made in the on-going clinical trial for INTASYL siRNA lead product candidate PH-762
September 18, 2025
·
4 min read
Press Releases
Cell and Gene Therapy Market Size Expected to Hit USD 119.30 Billion by 2034
September 18, 2025
·
1 min read
Layoffs
Novo, BMS Layoffs Hit New Jersey Hard With More Than 500 Left Jobless
Both BMS and Novo Nordisk have, in recent months, announced steep layoffs as they strive to cut back on costs.
September 18, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Frame Bio Licenses Novel Drug Delivery Technology from Mercury Bio to Develop Regenerative Therapies for Bone and Collagen Diseases and Disorders
September 18, 2025
·
1 min read
Immunology and inflammation
Roivant, Pfizer’s Therapy Shows ‘Patient-Centered Benefit’ in Rare Inflammatory Condition
Brepocitinib remains “ahead of competition” in the dermatomyositis space, according to analysts at Leerink, who projected that the drug candidate could hit $2 billion in sales in 2032.
September 18, 2025
·
2 min read
·
Tristan Manalac
Pain
Lexicon Backs Phase III Go Decision for Non-Opioid Pain Med With Post-Hoc Analysis
Supporting Lexicon Pharmaceuticals’ decision to advance the non-opioid analgesic pilavapadin into late-stage development—despite a topline miss in March—is an “improving” regulatory environment for non-addictive options for chronic pain, according to analysts at Jefferies.
September 18, 2025
·
2 min read
·
Tristan Manalac
1 of 85,831
Next
